We are very pleased to have had so many experts, partners, and friends joining our Summer Get-together this year! It was an incredible day filled…
Adrian Limani04.08.2023
Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime…
Adrian Limani22.06.2023
How Swiss life sciences startups can compete globally In this biotech networking event, Johnson & Johnson Innovation shared their approach towards external innovation and their…
Adrian Limani06.06.2023
Bridge Biotherapeutics’ partnering strategy and growth by external innovation In this biotech networking event, two speakers from Bridge Biotherapeutics talked about the history of their…
Adrian Limani25.05.2023
Phialogics AG has announced the appointment of Prof. Dr. Erich Schlick as Chairman of its Board of Directors. Erich was introduced to Phialogics by BaseLaunch…
Adrian Limani12.05.2023
Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…
Adrian Limani21.04.2023
Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…
Adrian Limani21.04.2023
We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M! Just the last…
Adrian Limani13.04.2023
Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…
Adrian Limani13.04.2023
